Literature DB >> 24633780

Population pharmacokinetic analysis of fexofenadine in Japanese pediatric patients.

Jean-Marie Martinez1, Sonia Khier, Shigemichi Morita, Clémence Rauch, David Fabre.   

Abstract

A population pharmacokinetic analysis was conducted to characterize the pharmacokinetics of fexofenadine in Japanese pediatric patients (6 months through 16 years) with perennial allergic rhinitis or atopic dermatitis. The dataset was composed of 515 patients (including 109 adults), for a total of 1,080 concentration-time points. The analysis was performed with NONMEM using the SAEM method. Several structural models and residual error models were evaluated. The relationship between the individual estimates and the potential covariates was then investigated: demographic and pathophysiologic characteristics were tested as potential model covariates (forward selection method). The qualification of the model was performed using visual predictive check and bootstrap. A two-compartment disposition model with first-order absorption best fitted the data. The inter-individual variability was modeled through an exponential error model for all parameters (except for ka for which no inter-individual term could be estimated), while a proportional error model was used to model the residual variability. The final model included two covariates on elimination clearance and one on the intercompartmental clearance. CL/F was related to BSA and patient's age (expressed in months) Q/F was also related to BSA. Once the model was correctly qualified, exposure parameters such as Cmax and AUCτ were computed and compared between each age sub-group and between Japanese and Caucasians patients. These comparisons did not reveal any major difference (less than 50 %) between subgroups.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24633780     DOI: 10.1007/s10928-014-9356-2

Source DB:  PubMed          Journal:  J Pharmacokinet Pharmacodyn        ISSN: 1567-567X            Impact factor:   2.745


  11 in total

1.  A Linux cluster for population pharmacokinetic analyses.

Authors:  H Speth
Journal:  Int J Clin Pharmacol Ther       Date:  2004-03       Impact factor: 1.366

2.  A formula to estimate the approximate surface area if height and weight be known. 1916.

Authors:  D Du Bois; E F Du Bois
Journal:  Nutrition       Date:  1989 Sep-Oct       Impact factor: 4.008

Review 3.  Dosing in children.

Authors:  N Holford
Journal:  Clin Pharmacol Ther       Date:  2010-01-20       Impact factor: 6.875

4.  Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models.

Authors:  Martin Bergstrand; Andrew C Hooker; Johan E Wallin; Mats O Karlsson
Journal:  AAPS J       Date:  2011-02-08       Impact factor: 4.009

5.  A size standard for pharmacokinetics.

Authors:  N H Holford
Journal:  Clin Pharmacokinet       Date:  1996-05       Impact factor: 6.447

6.  Evaluating pharmacokinetic/pharmacodynamic models using the posterior predictive check.

Authors:  Y Yano; S L Beal; L B Sheiner
Journal:  J Pharmacokinet Pharmacodyn       Date:  2001-04       Impact factor: 2.745

7.  Pharmacokinetics of fexofenadine: evaluation of a microdose and assessment of absolute oral bioavailability.

Authors:  Graham Lappin; Yoko Shishikura; Roeline Jochemsen; Richard John Weaver; Charlotte Gesson; Brian Houston; Berend Oosterhuis; Ole J Bjerrum; Malcolm Rowland; Colin Garner
Journal:  Eur J Pharm Sci       Date:  2010-03-20       Impact factor: 4.384

8.  The utility of mixed-effects covariate analysis in rapid selection of doses in pediatric subjects: a case study with fexofenadine hydrochloride.

Authors:  Rajesh Krishna; Sriram Krishnaswami; Barbara Kittner; Abdul J Sankoh; Bradford K Jensen
Journal:  Biopharm Drug Dispos       Date:  2004-12       Impact factor: 1.627

Review 9.  Facilitation of drug evaluation in children by population methods and modelling.

Authors:  Michel Tod; Vincent Jullien; Gérard Pons
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

Review 10.  Clinical pharmacokinetics and pharmacodynamics of desloratadine, fexofenadine and levocetirizine : a comparative review.

Authors:  Philippe Devillier; Nicolas Roche; Christophe Faisy
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

View more
  1 in total

Review 1.  Development of Human Membrane Transporters: Drug Disposition and Pharmacogenetics.

Authors:  Miriam G Mooij; Anne T Nies; Catherijne A J Knibbe; Elke Schaeffeler; Dick Tibboel; Matthias Schwab; Saskia N de Wildt
Journal:  Clin Pharmacokinet       Date:  2016-05       Impact factor: 6.447

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.